Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood

• Published in: Pediatric research 2022-07, Vol.92 (1), p.307-314
• Main Authors: Rancken, Elina J., Metsäranta, Marjo P. H., Gissler, Mika, Rahkonen, Leena K., Haataja, Leena M.
• Format: Article
• Language: English
• Subjects: Anemia, Neonatal - chemically induced; Autism Spectrum Disorder - chemically induced; Biomarkers; Child; Child, Preschool; Childhood; Erythrocyte Transfusion; Erythropoietin; Female; Gestational age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Morbidity; Neurodevelopmental disorders; Neurodevelopmental Disorders - epidemiology; Pediatric Surgery; Pediatrics; Population Study; Population Study Article; Umbilical cord
• ISSN: 0031-3998; 1530-0447; 1530-0447
• DOI: 10.1038/s41390-021-01679-0

Background New biomarkers that predict later neurodevelopmental morbidity are needed. This study evaluated the associations between umbilical cord serum erythropoietin (us-EPO) and neurodevelopmental morbidity by the age of 2–6.5 years in a Finnish cohort. Methods This study included 878 non-anomalous children born alive in 2012 to 2016 in Helsinki University Hospitals and whose us-EPO concentration was determined at birth. Data of these children were linked to data from the Finnish Medical Birth Register and the Finnish Hospital Discharge Register. Neurodevelopmental morbidity included cerebral palsy, epilepsy, intellectual disability, autism spectrum disorder, sensorineural defects, and minor neurodevelopmental disorders. Results In the cohort including both term and preterm children, us-EPO levels correlated with gestational age ( r  = 0.526) and were lower in premature children. High us-EPO levels (>100 IU/l) were associated with an increased risk of severe neurodevelopmental morbidity (OR: 4.87; 95% CI: 1.05–22.58) when adjusted for the gestational age. The distribution of us-EPO levels did not differ in children with or without the later neurodevelopmental diagnosis. Conclusions Although high us-EPO concentration at birth was associated with an increased risk of neurodevelopmental morbidity in early childhood, the role of us-EPO determination in clinical use appears to be minor. Impact We determined whether endogenous umbilical cord serum erythropoietin would be a new useful biomarker to predict the risk of neurodevelopmental morbidity. This study evaluated the role of endogenous erythropoietin at birth in neurodevelopmental morbidity with a study population of good size and specific diagnoses based on data from high-quality registers. Although high umbilical cord serum erythropoietin concentration at birth was associated with an increased risk of neurodevelopmental morbidity in early childhood, the clinical value of erythropoietin determination appears to be minor.